SHAREHOLDER ALERT Preliminary Testing Complete
Post# of 72440
Preliminary Testing Complete on Brilacidin for Coronavirus (Covid-19), Results as Early as Today
March 31, 2020 - As previously disclosed, research is being conducted on Brilacidin as a novel therapeutic against SARS-CoV-2, the coronavirus responsible for Covid-19, at one of the 13 U.S. Regional Biocontainment Laboratories (RBL). The Company was informed late Monday by researchers at the RBL that preliminary testing has been completed and to expect the results as early as today. Subsequently, the results will be released to the public.
We look forward to keeping you apprised of the latest developments in our efforts to fight the Covid-19 pandemic.